BridgeBio Pharma (BBIO) Cash from Operations (2018 - 2026)

BridgeBio Pharma has disclosed Cash from Operations across 9 years of filings, most recently posting 197279000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 197279000.0, up 0.98% year-over-year; the trailing twelve-month figure through Mar 2026 was 443954000.0 (up 11.28% YoY), and the FY2025 annual result was 445910000.0, up 14.37% from the prior year.
• Cash from Operations came in at 197279000.0 for Q1 2026 at BridgeBio Pharma, down from 56420000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 74703000.0 in Q2 2024 to a low of 219537000.0 in Q1 2024.
• The 5-year median for Cash from Operations is 135163000.0 (2022), against an average of 124184058.82.
• Across the five-year window, Cash from Operations plunged 272.22% in 2023 and jumped 165.9% in 2024, its largest moves.
• BridgeBio Pharma's Cash from Operations stood at 93243000.0 in 2022, then slumped by 33.86% to 124819000.0 in 2023, then plunged by 56.49% to 195326000.0 in 2024, then jumped by 71.11% to 56420000.0 in 2025, then tumbled by 249.66% to 197279000.0 in 2026.
• The last three Cash from Operations figures came in at 197279000.0 (Q1 2026), 56420000.0 (Q4 2025), and 109574000.0 (Q3 2025), per Business Quant data.